Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

eet regulatory requirements. The Group is also subject to the risk that suppliers will not be able to meet the quantities needed to meet market requirements

The development and approval of the Group's products depends on the ability to procure active ingredients and special packaging materials from sources approved by regulatory authorities. As the marketing approval process requires manufacturers to specify their own proposed suppliers of active ingredients and special packaging materials in their applications, regulatory approval of a new supplier would be required if active ingredients or such packaging materials were no longer available from the supplier specified in the marketing approval. The need to qualify a new supplier could delay the Group's development and commercialization efforts.

The Group uses bovine-derived serum sourced from New Zealand and North America in the manufacturing processes for REPLAGAL and ELAPRASE. The discovery of additional cattle in North America or the discovery of cattle in New Zealand with bovine spongiform encephalopathy, or mad cow disease, could cause the regulatory agencies in some countries to impose restrictions on these products, or prohibit the Group from using these products at all in such countries.

The actions of certain customers can affect the Group's ability to sell or market products profitably, as well as impact net sales and growth comparisons

A small number of large wholesale distributors control a significant share of the US and European markets. In 2008, for example, approximately 56% of the Group's product sales were attributable to two customers; McKesson Corp. and Cardinal Health, Inc. In the event of financial failure of any of these customers, the Group may suffer financial loss and a decline in revenues and earnings. In addition, the number of independent drug stores and small chains has decreased as retail pharmacy consolida
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... CA (PRWEB) May 17, 2013 IAC Industries ... Technologies, a start up laboratory needing to set up and ... moving to a larger facility within a year’s time. How ... knowledge that the laboratory is temporary? What is efficient and ... Series modular workstations from IAC Industries. The planners at DisperSol ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... GBS and EV Expand GeneXpert(R) Test Menu in ... Cepheid (Nasdaq:,CPHD) today announced that Health Canada ... the rapid detection of Group B Streptococcus (GBS),and ... EV-associated,meningitis. These tests join Xpert MRSA, which received ...
... 3 American Oriental,Bioengineering (NYSE: AOB ) ... private,offer, subject to market conditions and other factors, ... of newly,issued convertible preferred stock. The convertible preferred ... arrears, and will be,convertible upon the occurrence of ...
... 3, 2008, TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO Kendle (Nasdaq: KNDL ... June 3 at 9:30 a.m. Eastern Time to,discuss the acquisition of ... provide an update on second quarter,progress. A question and answer session ...
Cached Biology Technology:Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 3Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 4American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock 2Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The AGA Research ... Augustyn and Damian Augustyn Award in Digestive Cancer, which ... School of Medicine at the University of Pennsylvania, Philadelphia, ... Zeb1 in pancreas development, regeneration and cancer progression. , ... award in honor of two distinguished clinicians and AGA ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... , PARIS , Feb. 4 ... Eurofins Scientific, a global leader in bio-analysis. , Under a ... connect 16 key Eurofins laboratories and research centers in ... company,s global customer base.  Verizon will use MPLS (multi-protocol label ...
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... College of Georgia researchers are seeking to refine cancer ... Chinese medicine. Celastrol, derived from trees and shrubs ... to treat symptoms such as fever, chills, joint pain ... play a role in cancer treatment by inactivating a ...
Cached Biology News:Verizon Business to Provide Global IP for Eurofins Scientific 2Verizon Business to Provide Global IP for Eurofins Scientific 3Scientists find quantum mechanics at work in photosynthesis 2Plant derivative could help refine cancer treatment 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: